LumiraDx Company Description
LumiraDx Limited operates as a point of care diagnostics company.
The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers.
It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions.
Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease.
The company is headquartered in London, the United Kingdom.
| Country | Cayman Islands |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,210 |
| CEO | Veronique Ameye |
Contact Details
Address: 3 More London Riverside London, SE1 2AQ United Kingdom | |
| Phone | 44 11 7284 2535 |
| Website | lumiradx.com |
Stock Details
| Ticker Symbol | LMDXF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Veronique Ameye EMBA, Esq., M.B.A. | Chief Executive Officer and General Counsel |
| Dorian LeBlanc CPA | Chief Financial Officer and Vice President of Global Operations |
| Colleen McMillen | Vice President of Communications |
| Andy Ward | National Sales Director - UK |
| David Walton DMS | Chief Commercial Officer |
| Giffin Daughtridge | President of North America Commercial Operations and Global Molecular Solutions |
| Melissa Garcia | Vice President and Corporate Counsel |